$TRUMP Aardvark Therapeutics shares rise
after FDA lifts clinical hold
Shares of Aardvark Therapeutics Inc. (NASDAQ:AARD) surged 21% in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its investigational drug ARD-101, which is being developed to treat hyperphagia associated with Prader-Willi syndrome.
The FDA imposed the hold in May 2026, after Aardvark voluntarily paused dosing in its Phase 3 HERO trial and open-label extension study on 27/02/2026. The pause followed the observation of reversible changes in electrocardiograms (ECGs) during routine safety monitoring in a separate study involving healthy volunteers.
$XAU
after FDA lifts clinical hold
Shares of Aardvark Therapeutics Inc. (NASDAQ:AARD) surged 21% in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its investigational drug ARD-101, which is being developed to treat hyperphagia associated with Prader-Willi syndrome.
The FDA imposed the hold in May 2026, after Aardvark voluntarily paused dosing in its Phase 3 HERO trial and open-label extension study on 27/02/2026. The pause followed the observation of reversible changes in electrocardiograms (ECGs) during routine safety monitoring in a separate study involving healthy volunteers.
$XAU